AR036856A2 - Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion - Google Patents
Clorhidrato de paroxetina anhidro, y procedimiento para su preparacionInfo
- Publication number
- AR036856A2 AR036856A2 ARP020103931A ARP020103931A AR036856A2 AR 036856 A2 AR036856 A2 AR 036856A2 AR P020103931 A ARP020103931 A AR P020103931A AR P020103931 A ARP020103931 A AR P020103931A AR 036856 A2 AR036856 A2 AR 036856A2
- Authority
- AR
- Argentina
- Prior art keywords
- characteristic peaks
- paroxetine hydrochloride
- hydrochloride anhydrous
- shows
- theta
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title 1
- 241000768714 Anoides Species 0.000 title 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title 1
- 229960002296 paroxetine Drugs 0.000 title 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 6
- 229960000656 paroxetine hydrochloride anhydrous Drugs 0.000 abstract 5
- 238000002844 melting Methods 0.000 abstract 3
- 230000008018 melting Effects 0.000 abstract 3
- 239000002243 precursor Substances 0.000 abstract 2
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 238000001228 spectrum Methods 0.000 abstract 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formas B, C y D de anhidro de clorhidrato de paroxetina que pueden ser utilizadas para tratar y prevenir desórdenes médicos, tales como depresión, desorden compulsivo obsesivo y pánico. El anhidro de clorhidrato de paroxetina en Forma B tiene un punto de fusión de alrededor de 138°C; bandas significativas IR a alrededor de 538, 574, 614, 675, 722, 762, 782, 815, 833, 884, 925, 938, 970, 986, 1006, 1039, 1069, 1094, 1114, 1142, 1182, 1230, 1274, 1304, 1488, 1510, 1574, 1604, 1631 cm-1; la endoterma de DSC, medida a 10°C por minuto muestra un máximo a aproximadamente 137°C en ambos un bol abierto y un bol cerrado; muestra también un difractograma de rayos X que incluye picos característicos a 5,7, 11,3, 12,4, 14,3 grados 2 theta y un espectro RMN de estado sólido que incluye los picos característicos a 154,6, 148,3, 150,1, 141,7, 142,7, 139,0 ppm. El anhidro de clorhidrato de paroxetina en Forma C tiene un punto de fusión de alrededor de 164°C, bandas significativas IR a alrededor de 540, 574, 615, 674, 720, 760, 779, 802, 829, 840, 886, 935, 965, 984, 1007, 1034, 1092, 1109, 1139, 1183, 1218, 1240, 1263, 1280, 1507, 1540, 1558, 1598, 1652 cm-1; la endoterma de DSC, medida a 10°C por minuto muestra un máximo a aproximadamente 161°C en ambos un bol abierto y un bol cerrado; muestra también un difractograma de rayos X que incluye picos característicos a 10,1, 12,1, 13,1, 14,3 grados 2 theta y un espectro RMN de estado sólido que incluye los picos característicos a 154,0, 148,5, 143,03, 140,4 ppm. El anhidro de clorhidrato de paroxetina en Forma D existe como un sólido semi-cristalino con un punto de fusión de alrededor de 125°C con características físicas similares a cuando es preparado a partir de un solvato precursor de tolueno, teniendo dicho solvato precursor de tolueno bandas significativas IR a alrededor de 1631, 1603, 1555, 1513, 1503, 1489, 1340, 1275, 1240, 1221, 1185, 1168, 1140, 1113, 1101, 1076, 1037, 1007, 986, 968, 935, 924, 885, 841, 818, 783, 760, 742, 720, 698, 672, 612, 572, 537 y 465 cm-1; y picos característicos de difracción de rayos X a 7,2, 9,3, 12,7, y 14,3 grados 2 theta. Se describe un procedimiento de preparación de anhidro de clorhidrato de paroxetina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9502297.6A GB9502297D0 (en) | 1995-02-06 | 1995-02-06 | Novel compound |
| GBGB9503112.6A GB9503112D0 (en) | 1995-02-17 | 1995-02-17 | Novel compound |
| GBGB9509807.5A GB9509807D0 (en) | 1995-05-15 | 1995-05-15 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036856A2 true AR036856A2 (es) | 2004-10-06 |
Family
ID=27267578
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960101230A AR001982A1 (es) | 1995-02-06 | 1996-02-01 | Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion |
| ARP020103931A AR036856A2 (es) | 1995-02-06 | 2002-10-18 | Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960101230A AR001982A1 (es) | 1995-02-06 | 1996-02-01 | Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion |
Country Status (47)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3882224B2 (ja) | 1996-05-31 | 2007-02-14 | 旭硝子株式会社 | パロキセチンの製造方法 |
| EP1384711A1 (en) * | 1996-06-13 | 2004-01-28 | SUMIKA FINE CHEMICALS Co., Ltd. | Optical resolution of a piperidine derivative |
| WO1998002556A2 (en) * | 1996-07-15 | 1998-01-22 | Smithkline Beecham Plc | Screening for and use of an esterase for a stereospecific resolution |
| US5672612A (en) * | 1996-09-09 | 1997-09-30 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
| US6638948B1 (en) | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
| CA2193939C (en) * | 1996-12-24 | 2002-02-12 | K.S. Keshava Murthy | Useful form of anhydrous paroxetine hydrochloride |
| ATE200781T1 (de) * | 1997-06-10 | 2001-05-15 | Synthon Bv | 4-phenylpiperidin-derivate |
| DK0903345T3 (da) * | 1997-08-08 | 2000-10-23 | Aventis Pharma Gmbh | Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid |
| GB9726907D0 (en) * | 1997-12-19 | 1998-02-18 | Smithkline Beecham Plc | Novel compounds |
| CN1300286A (zh) * | 1998-03-16 | 2001-06-20 | 史密丝克莱恩比彻姆有限公司 | 帕罗西丁的晶形 |
| AU2003200534B2 (en) * | 1998-03-24 | 2004-12-02 | Smithkline Beecham Plc | Paroxetine compositions |
| GB9806312D0 (en) * | 1998-03-24 | 1998-05-20 | Smithkline Beecham Plc | Novel formulations |
| US6699882B2 (en) | 1998-03-24 | 2004-03-02 | Smithkline Beecham P.L.C. | Paroxetine compositions |
| JP3796351B2 (ja) | 1998-04-13 | 2006-07-12 | 住友化学株式会社 | パロキセチン塩酸塩無水和物の乾燥方法 |
| GB9812941D0 (en) * | 1998-06-16 | 1998-08-12 | Smithkline Beecham Plc | Method of treatment |
| CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
| ES2138937B1 (es) | 1998-07-07 | 2000-10-01 | Medichem Sa | Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen. |
| CN1321155A (zh) * | 1998-08-07 | 2001-11-07 | 史密丝克莱恩比彻姆有限公司 | 制备非晶性脱水型帕罗西汀盐酸盐的方法 |
| GB9824298D0 (en) * | 1998-11-05 | 1998-12-30 | Smithkline Beecham Plc | Novel process |
| GB9826175D0 (en) * | 1998-11-28 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
| GB9826176D0 (en) * | 1998-11-28 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
| GB9826178D0 (en) * | 1998-11-30 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
| PT1135383E (pt) * | 1998-11-30 | 2004-04-30 | Smithkline Beecham Plc | Solvatos mistos de propan-2-ol de paroxetina |
| GB9826171D0 (en) * | 1998-11-30 | 1999-01-20 | Smithkline Beecham Plc | Novel compounds |
| GB9826180D0 (en) * | 1998-11-30 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
| GB9826242D0 (en) * | 1998-11-30 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
| GB9828767D0 (en) * | 1998-12-29 | 1999-02-17 | Smithkline Beecham Plc | Novel process |
| IT1308629B1 (it) * | 1999-02-23 | 2002-01-09 | Recordati Chem Pharm | Processo per la produzione di paroxetina. |
| EP1161241B1 (de) * | 1999-03-12 | 2005-12-07 | Aesica Pharmaceuticals Ltd. | Stabile pharmazeutische anwendungsform für paroxetin-anhydrat |
| GB9914585D0 (en) * | 1999-06-22 | 1999-08-25 | Smithkline Beecham Plc | Novel process |
| GB9914583D0 (en) * | 1999-06-22 | 1999-08-25 | Smithkline Beecham Plc | Novel process |
| SE9902550D0 (sv) * | 1999-07-02 | 1999-07-02 | Astra Ab | New crystalline forms |
| GB9919001D0 (en) * | 1999-08-12 | 1999-10-13 | Smithkline Beecham Plc | Novel process |
| GB9923445D0 (en) * | 1999-10-04 | 1999-12-08 | Smithkline Beecham Plc | Novel process |
| GB9923446D0 (en) * | 1999-10-04 | 1999-12-08 | Smithkline Beecham Plc | Novel process |
| GB9923439D0 (en) * | 1999-10-04 | 1999-12-08 | Smithkline Beecham Plc | Novel process |
| HU226912B1 (en) * | 2000-04-07 | 2010-03-01 | Richter Gedeon Nyrt | New paroxetin salt and medicament containing it |
| JPWO2002022609A1 (ja) * | 2000-09-14 | 2004-01-22 | 旭硝子株式会社 | 実質的に有機溶媒を含まないパロキセチン塩類の製造方法 |
| CA2476723A1 (en) * | 2002-02-22 | 2003-09-04 | Gideon Pilarski | Preparation of paroxetine involving novel intermediates |
| CA2625299A1 (en) * | 2005-11-22 | 2007-05-31 | Teva Pharmaceutical Industries Ltd. | Crystal forms of cinacalcet hci and processes for their preparation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
| EP0223403B1 (en) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
| US5017585A (en) * | 1986-11-03 | 1991-05-21 | Novo Nordisk A/S | Method of treating calcium overload |
| GB8626936D0 (en) * | 1986-11-11 | 1986-12-10 | Ferrosan As | Treatment |
| DK715988D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Etherifikation og dealkylering af piperidin-derivater samt intermediater |
| DK716088D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Reduktion af piperidin-dion-derivater samt intermediat |
| US5371092A (en) * | 1990-11-24 | 1994-12-06 | Beecham Group, P.L.C. | Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia |
| US5258517A (en) * | 1992-08-06 | 1993-11-02 | Sepracor, Inc. | Method of preparing optically pure precursors of paroxetine |
| GB9325644D0 (en) * | 1993-12-15 | 1994-02-16 | Smithkline Beecham Plc | Novel formulation |
-
1996
- 1996-02-01 AR ARP960101230A patent/AR001982A1/es not_active Application Discontinuation
- 1996-02-01 SK SK143-96A patent/SK283608B6/sk not_active IP Right Cessation
- 1996-02-02 EP EP03078024A patent/EP1378508A1/en not_active Withdrawn
- 1996-02-02 MC MC2329A patent/MC2411A1/fr unknown
- 1996-02-02 DE DE1996631298 patent/DE69631298T2/de not_active Expired - Lifetime
- 1996-02-02 WO PCT/EP1996/000447 patent/WO1996024595A1/en not_active Ceased
- 1996-02-02 DE DE69621777T patent/DE69621777T2/de not_active Expired - Lifetime
- 1996-02-02 IE IE960104A patent/IE80500B1/en not_active IP Right Cessation
- 1996-02-02 AU AU43328/96A patent/AU701518C/en not_active Ceased
- 1996-02-02 AU AU47864/96A patent/AU4786496A/en not_active Abandoned
- 1996-02-02 MX MX9600484A patent/MX9600484A/es not_active IP Right Cessation
- 1996-02-02 RO RO96-00183A patent/RO112426B1/ro unknown
- 1996-02-02 FR FR9601297A patent/FR2730232B1/fr not_active Expired - Fee Related
- 1996-02-02 DE DE19603797A patent/DE19603797C2/de not_active Revoked
- 1996-02-02 MY MYPI96000383A patent/MY132529A/en unknown
- 1996-02-02 EP EP96903970A patent/EP0808314B1/en not_active Expired - Lifetime
- 1996-02-02 BR BR9600534A patent/BR9600534A/pt not_active IP Right Cessation
- 1996-02-02 EP EP01115079A patent/EP1136490B1/en not_active Expired - Lifetime
- 1996-02-02 CZ CZ0032096A patent/CZ297171B6/cs not_active IP Right Cessation
- 1996-02-02 LV LVP-96-31A patent/LV11618B/en unknown
- 1996-02-03 KR KR1019960002620A patent/KR100289885B1/ko not_active Expired - Fee Related
- 1996-02-03 SG SG1996000861A patent/SG43787A1/en unknown
- 1996-02-04 DZ DZ960030A patent/DZ1989A1/fr active
- 1996-02-05 BG BG100333A patent/BG62967B1/bg unknown
- 1996-02-05 IL IL11703596A patent/IL117035A/xx unknown
- 1996-02-05 GR GR960100038A patent/GR1002466B/el not_active IP Right Cessation
- 1996-02-05 MA MA24157A patent/MA23802A1/fr unknown
- 1996-02-05 HU HU9600255A patent/HUP9600255A1/hu unknown
- 1996-02-05 LU LU88711A patent/LU88711A1/fr unknown
- 1996-02-05 DK DK011996A patent/DK11996A/da not_active Application Discontinuation
- 1996-02-05 NO NO960472A patent/NO301009B1/no not_active IP Right Cessation
- 1996-02-05 SE SE9600406A patent/SE521084C2/sv not_active IP Right Cessation
- 1996-02-05 RU RU96102180A patent/RU2125052C1/ru not_active IP Right Cessation
- 1996-02-05 PL PL96312646A patent/PL189247B1/pl unknown
- 1996-02-05 FI FI960519A patent/FI111544B/fi not_active IP Right Cessation
- 1996-02-05 CN CN96103526A patent/CN1090187C/zh not_active Expired - Fee Related
- 1996-02-05 SI SI9600378A patent/SI21923B/sl not_active IP Right Cessation
- 1996-02-05 CA CA002168829A patent/CA2168829C/en not_active Expired - Fee Related
- 1996-02-05 BE BE9600101A patent/BE1009112A3/fr not_active IP Right Cessation
- 1996-02-05 UA UA96020442A patent/UA49796C2/uk unknown
- 1996-02-05 NL NL1002248A patent/NL1002248C2/xx not_active IP Right Cessation
- 1996-02-05 TW TW085101374A patent/TW503238B/zh not_active IP Right Cessation
- 1996-02-05 NZ NZ280943A patent/NZ280943A/en not_active IP Right Cessation
- 1996-02-05 SI SI9600036A patent/SI9600036B/sl not_active IP Right Cessation
- 1996-02-05 IT IT96MI000203A patent/IT1289532B1/it active IP Right Grant
- 1996-02-05 JP JP8018679A patent/JP2915338B2/ja not_active Expired - Fee Related
- 1996-02-05 AT AT0021096A patent/AT407528B/de not_active IP Right Cessation
- 1996-02-05 CN CNB2004100855519A patent/CN1289496C/zh not_active Expired - Fee Related
- 1996-02-05 CA CA002211522A patent/CA2211522C/en not_active Expired - Fee Related
- 1996-02-05 ES ES09600262A patent/ES2114471B1/es not_active Expired - Fee Related
- 1996-02-05 CA CA002210022A patent/CA2210022C/en not_active Expired - Fee Related
- 1996-02-06 CH CH02051/98A patent/CH689804A5/de not_active IP Right Cessation
- 1996-02-06 CH CH01510/97A patent/CH689229A5/de not_active IP Right Cessation
- 1996-02-06 TR TR96/00096A patent/TR199600096A2/xx unknown
- 1996-02-06 PT PT101827A patent/PT101827B/pt not_active IP Right Cessation
- 1996-02-06 CH CH00304/96A patent/CH688353A5/de not_active IP Right Cessation
- 1996-02-06 OA OA60773A patent/OA10261A/en unknown
-
1997
- 1997-02-28 NO NO19970939A patent/NO311519B1/no not_active IP Right Cessation
- 1997-05-08 HK HK59397A patent/HK59397A/xx not_active IP Right Cessation
-
1998
- 1998-12-02 JP JP10342812A patent/JPH11228571A/ja active Pending
-
2000
- 2000-08-31 CN CN001268872A patent/CN1216055C/zh not_active Expired - Fee Related
-
2001
- 2001-02-12 DK DKPA200100223 patent/DK200100223A/da not_active Application Discontinuation
- 2001-10-18 NO NO20015070A patent/NO20015070D0/no not_active Application Discontinuation
-
2002
- 2002-10-18 AR ARP020103931A patent/AR036856A2/es unknown
-
2003
- 2003-02-03 FI FI20030162A patent/FI20030162A7/fi unknown
- 2003-03-12 FI FI20030370A patent/FI20030370A7/fi not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036856A2 (es) | Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion | |
| TW200628152A (en) | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorsers | |
| WO2002074758A3 (en) | Novel amines as histamine-3 receptor ligands and their therapeutic applications | |
| DE60024588D1 (de) | Substituierte porphyrine und deren therapeutische verwendungen | |
| WO2003089434A3 (en) | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF | |
| MXPA05003093A (es) | Diaril eteres como antagonistas de receptor opiode. | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| SG158731A1 (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| WO2000051546A3 (en) | Bupropion metabolites and methods of their synthesis and use | |
| HU9602409D0 (en) | Prodrugs of morpholine tachykinin receptor antagonists | |
| ES2117090T3 (es) | Procedimiento para obtener formas granulares de aditivos para polimeros organicos. | |
| DK1156798T3 (da) | Felbamat-afledte forbindelser | |
| NO2012015I1 (no) | Dapoxetine i en hver form beskyttet av basis patent nr 330562 | |
| ATE212345T1 (de) | Heterocyclische verbindungen und ihre herstellung und verwendung | |
| DE69414554D1 (de) | Heterocyclische verbindungen und ihre herstellung und verwendung | |
| WO2002036135A3 (en) | Compositions for antitumour treatment containing ecteinascidin 743 | |
| CA2353133A1 (en) | Treatment of disorders secondary to organic impairments | |
| GB9923077D0 (en) | Sapogenin derivatives and their use | |
| MX9306215A (es) | Composicion novedosa para terapia peroral de un deterioro de la cognicion y un proceso para la fabricacion de la misma. | |
| MX9305248A (es) | Compuestos de diarilpiperazinoacetamida. | |
| SE8503207D0 (sv) | Pharmacologically active substituted benzamides | |
| SE8801845D0 (sv) | Pharmacologically active substituted benzamides | |
| TR200301330T2 (tr) | Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi. | |
| PL352551A1 (en) | C16 unsaturated analoques of prostaglandines selective in respect to fp | |
| AP9801202A0 (en) | Atropisomers of 3-heteroaryl-4(3H)-quinazolinones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |